Bristol Myers bets $4B on Turning Point and its targeted cancer drugs
Bio Pharma Dive
JUNE 3, 2022
Dive Brief: Bristol Myers Squibb is buying biotech Turning Point Therapeutics, announcing Friday a $4.1 billion deal that will give the pharmaceutical company an experimental drug that targets mutations found in lung cancer and other solid tumors. The deal values Turning Point at $76 a sh.
Let's personalize your content